Sec Form 13D Filing - BUNKA CHRISTOPHER filing for Lexaria Bioscience Corp. (LEXX) - 2021-02-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934
(Amendment No. 9)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

____________ 

¹ Calculation based on 5,104,332 shares of Common Stock issued and outstanding as of February 23, 2021. Includes 215,911 shares held in the name of C.A.B. Financial Services Ltd. and 237,543 shares held directly by Christopher Bunka. Includes 23,334 options exercisable at $10.20 and 6,667 warrants exercisable at $10.50 within the next sixty days.

^{____________________}

¹ Calculation based on 5,104,332 shares of Common Stock issued and outstanding as of February 23, 2021 and the assumption that 6,667 share purchase warrants held by C.A.B. Financial Service Ltd. and convertible into equity securities within sixty days are exercised. Christopher Bunka has voting and investment power over these securities.

Item 1. Security and Issuer

This Amendment No. 9 to the Statement on Schedule 13D amends the Statement on Schedule 13D originally filed with the Securities and Exchange Commission on February 8, 2010 as amended on November 29, 2010, November 18, 2011, January 28, 2013, January 29, 2015, March 4, 2015, August 6, 2015 and September 4, 2015. This Schedule 13D is being filed jointly on behalf of Christopher Bunka and C.A.B. Financial Services Ltd., (together the "Reporting Persons") relating to the shares of common stock, par value $0.001 ("Shares") of Lexaria Bioscience Corp., a corporation formed under the laws of the State of Nevada (the "Issuer"). The principal executive office of the Issuer is 100 – 740 McCurdy Road, Kelowna BC V1X 2P7.

This Amendment No. 9 to Schedule 13D amends and supplements the previously filed Schedule 13D as follows.

Item 2. Identity and Background.

Christopher Bunka

C.A.B Financial Services Ltd.

Item 3. Source and Amount of Funds or Other Consideration

The information set forth in Item 3 of the Schedule 13D is amended and restated as follows:

The Shares acquired by the Reporting Persons since the last amendment to the Schedule 13D were either acquired pursuant to a stock award initially awarded as compensation for the Reporting Person’s services as Chief Executive Officer of the Issuer, purchased via an exercise of warrants or options or purchased on the open market at fair market value. All amounts paid by the Reporting Persons for the acquisition of the Issuer’s Shares were from personal funds. A breakdown is as follows:

Mr. Bunka also disposed of 16,667 Shares, pursuant to a charitable donation, during this time period.

The Reporting Persons acquired certain Shares for investment purposes, received certain Shares as executive compensation and acquired certain Shares upon exercise of warrants (as indicated above in Item 3). Depending on market conditions and other factors, the Reporting Persons may acquire additional shares of the Issuer’s common stock as it deems appropriate, whether in open market purchases, privately negotiated transactions or otherwise. The Reporting Persons also reserve the right to dispose of some or all of the shares in the open market, in privately negotiated transactions to third parties or otherwise.

The Reporting Persons expect to evaluate on an ongoing basis the investment in the Issuer, and may from time to time acquire additional or dispose of shares of common stock (in each case, depending upon general investment policies, market conditions and other factors) or formulate other purposes, plans or proposals regarding the Issuer or the common stock held by the Reporting Persons to the extent deemed advisable in light of general investment policies, market conditions and other factors. Any such acquisitions or dispositions may be made, subject to applicable law, in open market transactions, privately negotiated transactions or, in the case of dispositions, pursuant to a registration statement. The Reporting Persons may act independently in evaluating and effecting any such transactions.

Except as set forth elsewhere in this Schedule 13D, none of the Reporting Persons has any plans or proposals which relate to or would result in:

Item 5. Interest in Securities of the Issuer

Item 5 to Schedule 13D is amended and restated as follows:

__________ 

¹ includes 23,334 shares of common stock acquirable on exercise of outstanding stock options within 60 days of the date hereof;

² includes 6,667 shares of common stock acquirable on exercise of outstanding share purchase warrants within 60 days of the date hereof;

³ Mr. Bunka beneficially owns all of the voting shares of C.A.B. Financial Services Ltd.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Except as referenced above or as described in Items 3, 4 and 5, to the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. The responses set forth in Item 3 hereof are incorporated by reference in their entirety.

Item 7. Material To Be Filed as Exhibits 

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.